Prevalence and Prognostic Impact of Metabolic Syndrome in Asymptomatic (Stage A and B Heart Failure) Patients

Metabolic Syndrome and Related Disorders

Volumn 14, Issue 3, 2016, Pages 187-194

  La Carrubba, Salvatore ^a   Antonini Canterin, Francesco ^b   Fabiani, Iacopo ^c   Colonna, Paolo ^d   Pugliese, Nicola Riccardo ^c   Caso, Pio ^e   Conte, Lorenzo ^c   Benedetto, Frank ^f   Zito, Concetta ^g   Citro, Rodolfo ^h   Carerj, Scipione ^g   Di Bello, Vitantonio ^b  

^a Ospedale Villa Sofia   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e MONALDI HOSPITAL   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; ASYMPTOMATIC DISEASE; CLINICAL TRIAL; COMPLICATION; HEART FAILURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR;

AGED; ASYMPTOMATIC DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 84961774599     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0143     Document Type: Article

References (50)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guide). J Am Coll Cardiol 2001;38:2101-2113.
2. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts an. Am J Cardiol 2001;88:1298-1300.
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-691.
4. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
5. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
6. Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med 2003;138:907-916.
7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421.
9. Butler J, Rodondi N, Zhu Y, et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006;47:1595-1602.
10. de Simone G, Devereux RB, Chinali M, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The Strong Heart Study. Diabetes Care 2007;30:1851-1856.
11. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006;119:812-819.
12. Arnlöv J, Ingelsson E, Sundström J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010;121:230-236.
13. Rigato M, Boscari F, Marcuzzo G, et al. Development of metabolic syndrome and electrocardiographic features of left ventricular hypertrophy in middle-aged working subjects. J Endocrinol Invest 2013;36:1027-1031.
14. Tang Z-H, Zeng F, Li Z, et al. The association and predictive value analysis of metabolic syndrome on diastolic heart failure in patients at high risk for coronary artery disease. Diabetol Metab Syndr 2013;5:30.
15. Rame JE. Chronic heart failure: A reversible metabolic syndrome? Circulation 2012;125:2809-2811.
16. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005;46:277-283.
17. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005;165: 1192-1198.
18. Nigam A, Bourassa MG, Fortier A, et al. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 2006;151:514-521.
19. Kranjcec D, AltabasV.Metabolic syndrome influencing infarct size and heart failure in patients with acute coronary syndrome: Does gender matter? Endocr J 2012;59:1065-1076.
20. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006;54:1317-1324.
21. Chen H-H, Wu C-J, Chen Y-C, et al. Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patientswith acute coronary syndrome. Coron Artery Dis 2006;17:593-596.
22. Voulgari C, Tentolouris N, Dilaveris P, et al. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol 2011;58:1343-1350.
23. Arnlöv J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 2001;142:720-724.
24. Sundström J, Risérus U, Byberg L, et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: Prospective, population based cohort study. BMJ 2006;332:878-882.
25. Wilson PWF. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072.
26. Li C, Ford ES, McGuire LC, et al. Association of metabolic syndrome and insulin resistance with congestive heart failure: Findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2007; 61:67-73.
27. Ingelsson E, Arnlöv J, Lind L, et al. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006; 92:1409-1413.
28. Wang TJ, Larson MG, Keyes MJ, et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-1353.
29. Quiñones MA, Douglas PS, Foster E, et al. ACC/AHA clinical competence statement on echocardiography: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. J Am Coll Cardiol 2003;41:687-708.
30. Lang RM, Badano LP, Mor-avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.
31. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a populationbased cohort. J Am Coll Cardiol 1999;33:1948-1955.
32. Khouri SJ, Maly GT, Suh DD, et al. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17:290-297.
33. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
34. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23: 469-480.
35. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med 2014;174: 15-22.
36. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.
37. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
38. Coats AJ, Anker SD, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000;35:S9-S14.
39. Hermida N, Markl A, Hamelet J, et al. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res 2013;99:44-54.
40. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity. J Am Coll Cardiol 2008;51:1775-1783.
41. Crendal E, Walther G, Vinet A, et al. Myocardial deformation and twist mechanics in adults with metabolic syndrome: Impact of cumulative metabolic burden. Obesity (Silver Spring) 2013;21:E679-E686.
42. Paneni F, Gregori M, Tocci G, et al. Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertens Res 2013;36: 36-42.
43. Grassi G, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: Characteristics and mechanisms. Hypertension 2007;49:535-541.
44. Antonini-Canterin F, Mateescu AD, Vriz O, et al. Cardiac structure and function and insulin resistance in morbidly obese patients: Does superobesity play an additional role? Cardiology 2014;127:144-151.
45. Carerj S, La Carrubba S, Antonini-Canterin F, et al. The incremental prognostic value of echocardiography in asymptomatic stage a heart failure. J Am Soc Echocardiogr 2010;23:1025-1034.
46. Di Bello V, La Carrubba S, Antonini-Canterin F, et al. Role of electrocardiography and echocardiography in prevention and predicting outcome of subjects at increased risk of heart failure. Eur J Prev Cardiol 2015;22:249-262.
47. Ayalon N, Gopal DM, Mooney DM, et al. Preclinical left ventricular diastolic dysfunction in metabolic syndrome. Am J Cardiol 2014;114:838-842.
48. Miura Y, Fukumoto Y, Miura T, et al. Impact of physical activity on cardiovascular events in patients with chronic heart failure. A multicenter prospective cohort study. Circ J 2013;77:2963-2972.
49. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112: 2735-2752.
50. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.